Canadian authorities have approved Lynparza (olaparib) as an oral treatment for people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA or ATM genes, both of which are involved in DNA repair. The approval, granted under priority review, is specifically indicated for patients who progressed after treatment with new forms of hormone therapy, such as Xtandi (enzalutamide) or Zytiga (abiraterone acetate). It makes Lynparza the first PARP inhibitor approved for prostate cancer in Canada. “The risk of developing prostate…
You must be logged in to read/download the full post.
The post Canada Approves Lynparza for Metastatic CRPC Patients With Certain Gene Mutations appeared first on BioNewsFeeds.